Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial - Finn, R; Ryoo, B; Merle, P (J Clin Oncol, 2020)
et al.